Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma

Van Le, Hoa; Van Naarden Braun, Kim; Nowakowski, Grzegorz S.; Sermer, David; Radford, John; Townsend, William; Ghesquieres, Herve; Menne, Tobias; Porpaczy, Edit; Fox, Christopher P.; Schusterbauer, Claudia; Liu, Fei Fei; Yue, Lihua; De Benedetti, Marc; Hasskarl, Jens

doi:10.1080/10428194.2022.2160200

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2023)
Working Paper

Background Sulfasalazine induced cytopenia, nephrotoxicity, and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend three monthly monitoring blood-tests indefinitely while others recommend stopping monitoring after one ye... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease (2023)
Journal Article

BACKGROUND: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment duration... Read More about Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Richter's transformation: Transforming the clinical landscape (2023)
Journal Article

Richter transformation (RT) represents an aggressive histological transformation from chronic lymphocytic leukaemia, most often to a large B cell lymphoma. It is characterised by chemo-resistance and subsequent short survival. Drug development has st... Read More about Richter's transformation: Transforming the clinical landscape.

Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis (2023)
Journal Article

Dosage of high‐dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse (2023)
Journal Article

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience (2023)
Journal Article

Bendamustine is among the most effective chemotherapeutics for indolent B-cell non- Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We conducted a... Read More about Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma (2023)
Journal Article

Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma associated with immunodeficiency, characterized by uncertain treatment approaches and an unfavourable prognosis. We conducted a multicenter, international, retrospective cohor... Read More about The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma.

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma (2023)
Journal Article

PURPOSE CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was designed to determine whether high-dose methotrexat... Read More about High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.

Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy (2023)
Journal Article

Primary Central Nervous System Lymphoma (PCNSL) is a highly malignant brain tumour. We investigated dynamic changes in tumour volume and apparent diffusion coefficient (ADC) measurements for predicting outcome following treatment with MATRix chemothe... Read More about Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy.

Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing (2023)
Journal Article

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia (2023)
Journal Article

Background: Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) have limited treatment options. Ceralasertib, a selective ataxia telangiectasia and Rad-3-related protein (ATR) inhibitor, demonstrated synergistic preclinical act... Read More about Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. (2023)
Journal Article

The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients considered unfit for fludarabine, cyclop... Read More about Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial..

Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study (2023)
Journal Article

This retrospective, observational study evaluated patterns of inpatient versus outpatient tumour lysis syndrome (TLS) monitoring during venetoclax ramp-up in 170 patients with chronic lymphocytic leukaemia. The primary outcome was clinical/biochemica... Read More about Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.

Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma (2023)
Journal Article

This study used a real-world population as a synthetic comparator for the single-arm TRANSCEND NHL 001 study (TRANSCEND; NCT02631044) to evaluate the efficacy of lisocabtagene maraleucel (liso-cel) compared with conventional (noncellular) therapies i... Read More about Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.

All Outputs (14)